Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax

Rhea-AI Filing Summary

Theravance Biopharma SVP Brett A. Grimaud had 8,829 Ordinary Shares withheld at $16.55 per share to cover taxes on vested restricted stock units. The shares were withheld by the company, not sold in the open market. After this tax-withholding transaction, he directly holds 363,120 Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Grimaud Brett A.

Role SVP, GEN COUNSEL AND SECRETARY

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares	8,829	$16.55	$146K

Holdings After Transaction: Ordinary Shares — 363,120 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Tax-withholding shares: 8,829 shares Withholding price: $16.55 per share Shares held after transaction: 363,120 shares +1 more

4 metrics

Tax-withholding shares 8,829 shares Withheld to satisfy tax obligations on vested RSUs

Withholding price $16.55 per share Price used for the 8,829 withheld shares

Shares held after transaction 363,120 shares Ordinary Shares directly held following tax withholding

Tax-withholding transactions 1 transaction Form 4 shows a single F-code tax-withholding event

Key Terms

restricted stock units, tax obligations, open market transaction, Ordinary Shares

4 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

open market transaction financial

"did not involve an open market transaction"

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grimaud Brett A.

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GEN COUNSEL AND SECRETARY

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/20/2026		F		8,829(1)	D	$16.55	363,120	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Theravance Biopharma (TBPH) insider Brett A. Grimaud report on this Form 4?

Brett A. Grimaud reported a tax-related share disposition. The company withheld 8,829 Ordinary Shares at $16.55 each to satisfy tax obligations from vesting restricted stock units, leaving him with 363,120 Ordinary Shares directly held afterward.

Was the Theravance Biopharma (TBPH) insider transaction an open market sale?

No, it was not an open market sale. The 8,829 shares were withheld by Theravance Biopharma to cover tax obligations from vested restricted stock units, as stated in the footnote, and the transaction occurred with the issuer, not in public trading.

How many Theravance Biopharma (TBPH) shares does Brett A. Grimaud hold after the tax withholding?

After the tax withholding, Brett A. Grimaud directly holds 363,120 Ordinary Shares. This figure reflects his position following the 8,829-share withholding to satisfy tax obligations tied to previously granted restricted stock units.

What was the price used for the Theravance Biopharma (TBPH) tax-withholding shares?

The tax-withholding disposition used a price of $16.55 per Ordinary Share. This price applied to the 8,829 shares withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units, according to the Form 4 details.

What does transaction code F mean in the Theravance Biopharma (TBPH) Form 4?

Transaction code F indicates shares were used to pay an exercise price or tax liability. Here, 8,829 shares were withheld to satisfy tax obligations from the vesting of restricted stock units, and the transaction occurred with the issuer rather than in the open market.